Awareness Gap: Many HS Patients Don’t Know About New Treatment Options
Close to three-quarters of hidradenitis suppurativa (HS) patients are unaware of U.S. Food and Drug Administration (FDA)-approved treatments, and 56% reported that their healthcare provider had not discussed these options with them.